Synthesis, structural characterization, cytotoxicity and encapsulation studies of N,Nʹ-(1, 2-dicyano-1,2-vinylene)-bis(4-hydroxysalicylideneaminato) di(p-chlorobenzyl)tin as potential anticancer drug

IF 1.8 3区化学 Q3 CHEMISTRY, INORGANIC & NUCLEAR

Main Group Metal Chemistry Pub Date : 2019-07-16 DOI:10.1515/mgmc-2019-0010

N.A.A. Mohd Amin, Rusnah Syahila Duali Hussen, See Mun Lee, K. Sim, S. Navanesan

{"title":"Synthesis, structural characterization, cytotoxicity and encapsulation studies of N,Nʹ-(1, 2-dicyano-1,2-vinylene)-bis(4-hydroxysalicylideneaminato) di(p-chlorobenzyl)tin as potential anticancer drug","authors":"N.A.A. Mohd Amin, Rusnah Syahila Duali Hussen, See Mun Lee, K. Sim, S. Navanesan","doi":"10.1515/mgmc-2019-0010","DOIUrl":null,"url":null,"abstract":"Abstract Two new diorganotin(IV) complexes with the general formula (RC7H6)2Sn(L) (where RC7H6 = p-ClBn, C1; and p-FBn, C2) were prepared based on the reaction of 2,3-bis(4-hydroxysalicylidene-amino)-maleic nitrile (L) with substituted dibenzyltin(IV) dichloride. The structures were confirmed by elemental analysis, Fourier transform infrared (FT-IR), proton and carbon nuclear magnetic resonance (1H and 13C NMR). They were tested against several cancer cell lines by using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. C1, which was most effective against MCF-7 breast cancer cell line, was further investigated in formulation and encapsulation studies, including drug encapsulation efficiency, particle size, morphology and in vitro drug release. An encapsulation of about 90% was achieved with particles of 128 nm average diameter. Field emission scanning electron microscopy (FESEM) confirmed a spherical shape for the encapsulated C1. The cumulative drug release over a period of 60 days in phosphate buffered saline (PBS) at pH 7.4 was 75%. Based on these results, the formulated drug has the potential of a slow release drug for cancer chemotherapy.","PeriodicalId":48891,"journal":{"name":"Main Group Metal Chemistry","volume":"42 1","pages":"101 - 94"},"PeriodicalIF":1.8000,"publicationDate":"2019-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/mgmc-2019-0010","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Main Group Metal Chemistry","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1515/mgmc-2019-0010","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, INORGANIC & NUCLEAR","Score":null,"Total":0}

引用次数: 3

Abstract

Abstract Two new diorganotin(IV) complexes with the general formula (RC7H6)2Sn(L) (where RC7H6 = p-ClBn, C1; and p-FBn, C2) were prepared based on the reaction of 2,3-bis(4-hydroxysalicylidene-amino)-maleic nitrile (L) with substituted dibenzyltin(IV) dichloride. The structures were confirmed by elemental analysis, Fourier transform infrared (FT-IR), proton and carbon nuclear magnetic resonance (1H and 13C NMR). They were tested against several cancer cell lines by using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. C1, which was most effective against MCF-7 breast cancer cell line, was further investigated in formulation and encapsulation studies, including drug encapsulation efficiency, particle size, morphology and in vitro drug release. An encapsulation of about 90% was achieved with particles of 128 nm average diameter. Field emission scanning electron microscopy (FESEM) confirmed a spherical shape for the encapsulated C1. The cumulative drug release over a period of 60 days in phosphate buffered saline (PBS) at pH 7.4 was 75%. Based on these results, the formulated drug has the potential of a slow release drug for cancer chemotherapy.

查看原文本刊更多论文

潜在抗癌药物N,N′-(1,2-二氰-1,2-乙烯基)-双(4-羟基水杨酸基氨基)二(对氯苯)锡的合成、结构表征、细胞毒性和包封研究

两种新的二有机锡(IV)配合物，通式为(RC7H6)2Sn(L)(其中RC7H6 = p-ClBn, C1;以2,3-二(4-羟基水杨基-氨基)-马来腈(L)与取代的二氯化二苄基锡(IV)为原料，制备了对- fbn, C2)。通过元素分析、傅里叶红外(FT-IR)、质子核磁共振和碳核磁共振(1H和13C NMR)对其结构进行了确证。使用MTT(3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四唑)测定法对几种癌细胞系进行了测试。C1对MCF-7乳腺癌细胞系最有效，我们进一步对其进行了配方和包封研究，包括药物包封效率、粒径、形态和体外释药。平均直径为128 nm的颗粒包封率约为90%。场发射扫描电子显微镜(FESEM)证实了封装的C1为球形。在pH 7.4的磷酸盐缓冲盐水(PBS)中，60天的累积药物释放量为75%。基于这些结果，该制剂具有作为癌症化疗缓释药物的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Main Group Metal Chemistry CHEMISTRY, INORGANIC & NUCLEAR-CHEMISTRY, ORGANIC

CiteScore

4.10

自引率

27.80%

发文量

审稿时长

4 weeks

期刊介绍： This journal is committed to the publication of short communications, original research, and review articles within the field of main group metal and semi-metal chemistry, Main Group Metal Chemistry is an open-access, peer-reviewed journal that publishes in ongoing way. Papers addressing the theoretical, spectroscopic, mechanistic and synthetic aspects of inorganic, coordination and organometallic main group metal and semi-metal compounds, including zinc, cadmium and mercury are welcome. The journal also publishes studies relating to environmental aspects of these metals, their toxicology, release pathways and fate. Articles on the applications of main group metal chemistry, including in the fields of polymer chemistry, agriculture, electronics and catalysis, are also accepted.